-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemΔιαβάστε περισσότεραSeamless listing, trading, clearing and settlement for fixed income
-
Trading
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemΔιαβάστε περισσότερα
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemΔιαβάστε περισσότερα
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeΔιαβάστε περισσότεραEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Διαβάστε περισσότεραThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indicesΔιαβάστε περισσότεραThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Διαβάστε περισσότεραShaping capital markets for future generations
Listing of biotech company arGEN-X on EnterNext in Brussels
10/07/2014
As of 10 July 2014 arGEN-X is listed on the Brussels markets. To celebrate this event, Tim Van Hauwermeiren, CEO of arGEN-X, opened the markets with a Bell Ceremony. Hans de Haard, co-founder of arGEN-X, had the honor to write the first opening price on the blackboard. The reference price was fixed at 8.50 euro.
arGEN-X specializes in researching and developing human monoclonal antibodies for the treatment of oncological, autoimmune and inflammatory diseases.
At the end of 2013, the company had a portfolio of 2 products in phase I of clinical development and 3 products in preclinical development phase.
The ticker code of arGEN-X is : ARGX.
If you would like to find out more : www.argen-x.com